BioNova Pharmaceuticals (Shanghai) Ltd.
PrivateLast Round
Series B
Extension
Nov 23, 2020
Total Funding Raised
$17M
Company Overview
BioNova Pharmaceuticals (Shanghai) Ltd. operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B Extension round in November 2020.
BioNova Pharmaceuticals (Shanghai) Ltd. is a biotechnology company that manufactures innovative drugs designed to advance clinical treatment for cancer and life-threatening diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioNova Pharmaceuticals (Shanghai) Ltd. Comparables
Compare BioNova Pharmaceuticals (Shanghai) Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innolake Biopharm | 72% | |
| Sutro Biopharma Inc | 70% | |
| Syndax Pharmaceuticals | 69% |
For institutional investors. Book with your work email.
BioNova Pharmaceuticals (Shanghai) Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Nov 23, 2020 | ||||
| Series B | Aug 1, 2020 | ||||
| Series A | Dec 25, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioNova Pharmaceuticals (Shanghai) Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series B |
| Mitsui Global Investment | Series B |
| TF Capital | Series A |
| Rencent Capital | Series B Extension |
| OrbiMed | Series B |
| Medfine Capital | Series B |
| Lilly Asia Ventures | Series B |
For institutional investors. Book with your work email.
BioNova Pharmaceuticals (Shanghai) Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioNova Pharmaceuticals (Shanghai) Ltd.'s valuation, stock price, and market status.
Is BioNova Pharmaceuticals (Shanghai) Ltd. a public or private company?
BioNova Pharmaceuticals (Shanghai) Ltd. is a private company.
What is the current stock price of BioNova Pharmaceuticals (Shanghai) Ltd.?
BioNova Pharmaceuticals (Shanghai) Ltd. is a private company, so its shares have no public market price. Caplight tracks BioNova Pharmaceuticals (Shanghai) Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioNova Pharmaceuticals (Shanghai) Ltd. worth (valuation)?
Valuation information for BioNova Pharmaceuticals (Shanghai) Ltd. is not publicly available.
Can I buy BioNova Pharmaceuticals (Shanghai) Ltd. stock?
BioNova Pharmaceuticals (Shanghai) Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioNova Pharmaceuticals (Shanghai) Ltd.'s last funding round?
BioNova Pharmaceuticals (Shanghai) Ltd.'s most recent funding round was Series B Extension on November 23, 2020.
Who are the main investors in BioNova Pharmaceuticals (Shanghai) Ltd.?
Key investors in BioNova Pharmaceuticals (Shanghai) Ltd. include BioTrack Capital, Mitsui Global Investment, TF Capital, Rencent Capital, OrbiMed.
Will BioNova Pharmaceuticals (Shanghai) Ltd. IPO soon?
No public IPO plans have been announced for BioNova Pharmaceuticals (Shanghai) Ltd..
How can I track BioNova Pharmaceuticals (Shanghai) Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in BioNova Pharmaceuticals (Shanghai) Ltd.'s shares on secondary markets.